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Abstract
The upper respiratory tract mucosa is the location for commensal Streptococcus (S.) pneumoniae colonization and therefore
represents a major site of contact between host and bacteria. The CD4
+ T cell response to pneumococcus is increasingly
recognised as an important mediator of immunity that protects against invasive disease, with data suggesting a critical role
for Th17 cells in mucosal clearance. By assessing CD4 T cell proliferative responses we demonstrate age-related
sequestration of Th1 and Th17 CD4
+ T cells reactive to pneumococcal protein antigens within mucosal lymphoid tissue.
CD25
hi T cell depletion and utilisation of pneumococcal specific MHCII tetramers revealed the presence of antigen specific
Tregs that utilised CTLA-4 and PDL-1 surface molecules to suppress these responses. The balance between mucosal effector
and regulatory CD4
+ T cell immunity is likely to be critical to pneumococcal commensalism and the prevention of unwanted
pathology associated with carriage. However, if dysregulated, such responses may render the host more susceptible to
invasive pneumococcal infection and adversely affect the successful implementation of both polysaccharide-conjugate and
novel protein-based pneumococcal vaccines.
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Introduction
Global estimates suggest that approximately one and a half million
deaths due to pneumonia, bacteraemia and meningitis are associated
with pneumococcal infection annually, around two thirds of these
occur in children in resource-poor countries [1–3]. In addition to this
high disease burden, S. pneumoniae is alsoa common commensal of the
upper respiratory tract colonising approximately 40–50% of children
from 0 to 2 years of age in the United Kingdom [4] and up to 90% of
African children in this same age group [5]. It is assumed that this
commensal relationship is regulated by natural immunity to the
pneumococcus, which is acquired from early infancy onwards [6].
This immunity is thought to result in a gradual decline in pneu-
mococcal carriage and infection with increasing age, even in settings
where the rates of invasive pneumococcal disease are high [7,8].
Classically, due to the undeniable protective efficacy of pneumo-
coccal capsular polysaccharide vaccines, anti-capsular antibodies
have been thought to be largely responsible for natural immunity to
S. pneumoniae [6,9]. As a consequence, studies assessing T cell
immunity to the pneumococcus, particularly in humans, have until
recently been lacking. However, re-evaluation of the epidemiology
has brought into question the central role of anti-capsular antibody
[6].Studiesofcolonization,antibodyacquisitionandtherelationship
with otitis media suggest that naturally-induced antibodies to
pneumococcal protein antigens may be protective against disease
[10]. The demonstration of CD4
+ T cells that respond to
pneumococcal protein antigens points to the possible contribution
of these cells to the development of serotype independent protection
against S. pneumoniae and the age-related decline in pneumococcal
disease [6,11–15]. Experiments in the mouse have shown cell-
mediated immunity to be an important protagonist in host immune
defence against pneumococcal colonization following immunization
with protein antigens. These studies have implicated the Th17 CD4
T cell subset in the promotion of mucosal clearance through the
recruitment of neutrophils and macrophages. Indeed, it has been
suggested that pneumolysin (Ply), a cytotoxic protein antigen and
TLR4 agonist which elicits protective immune responses in rodent
challenge models, is essential to the generation of Th17 responses to
S. pneumoniae [11,14,16].
We have investigated the nature of CD4 T cell immunity in the
upper respiratory tract with increasing age, and the relationship
between immunity at this site and that seen in the circulation. In
addition, we have determined whether pneumococcus-specific
Treg cells arise as a result of natural exposure and whether such
cells modulate the nature of protective responses.
Results
Anti-pneumococcal CD4
+ T cell responses are greater in
mucosal lymphoid tissue than in the blood
S. pneumoniae can inhabit the upper respiratory tract, particularly
during childhood [6,10] leading to nasopharyngeal colonisation
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002396[17,18]. Multiple colonization events are likely to occur through-
out life commencing from early infancy when they are most
frequent. Due to ongoing bacterial exposure in the upper
respiratory tract, lymphoid tissues within this anatomical site are
likely locations for immune induction and depots for pneumococ-
cal reactive lymphocytes. Support for this comes from a previous
study assessing tonsil and blood CD4
+ T cell responses to
pneumococcal proteins which hinted at higher responses by
tonsillar CD4
+ T cells compared to those from blood [13]. To test
this, we first compared CD4
+ T cell responses to S. pneumoniae in
upper respiratory tract lymphoid tissue with that in blood. Tonsil
mononuclear cells (MNC) were cultured with recombinant
pneumococcal Ply mutant protein [19] or supernatants generated
from the culture of type 2 D39 S. pneumoniae bacterial cells (SPNT)
as described previously [10,12]. CD4
+ T cell proliferation was
assessed after seven to nine days stimulation via 5, 6-Carboxy-
fluorescein diacetate succinimidyl ester (CFSE) staining and flow
cytometric analysis (Figure 1a). When similar data from eight adult
subjects (.20years old) was analysed, the mean percentage of
CD4+ T cells proliferating to Ply was 33.5% (66%) and SPNT
was 40.3% (65.9%). Proliferation to a previously established
positive control, influenza [20] was 49.2% (66.9%) and to the
negative control of media alone, 24.1% (66.2%); thus proliferative
responses to all three antigens were significantly greater (p ,0.05)
than the background proliferation (Figure 1b). The results reveal
that anti-pneumococcal CD4
+ T cell responses are evident in the
palatine tonsil mucosal lymphoid tissues of adults.
In order to compare the anti-pneumococcal immune responses
in the tonsil with those systemically, we analysed paired tonsil and
peripheral blood mononuclear cells (PBMC) CD4 T cell
proliferative responses. Comparison of CD4
+ cell proliferative
response to both Ply and SPNT stimulation similarly revealed
stronger anti-pneumococcal responses by tonsil compared to blood
CD4
+ T cells (Figure 1c). This stronger tonsillar response occurred
despite the subtraction of a slightly higher level of background
response in a number of the tonsil samples, which might have been
expected to mitigate against seeing such a difference. The response
to influenza was similar in both compartments. These results
suggest that pneumococcal-specific CD4
+ T cell may be
preferentially sequestered within mucosal lymphoid tissues located
in the upper respiratory tract, the anatomical site for bacterial
colonization.
As the decline in pneumococcal carriage and invasive disease is
thought to be the consequence of age-associated acquisition of
natural adaptive anti-pneumococcal immune responses [4,5], we
next examined the mucosal CD4 T cell- mediated response to the
pneumococcus from early infancy to mid-life. Evaluation of the
proliferative response to Ply and SPNT by CD4
+ cells of subjects
aged between 2 to 39 years old revealed a gradual increase in
responses with age, up to around early to mid-twenties and then a
plateau thereafter (Figure 2a). For anti-Ply responses the average
rate of increase in the percentage of proliferating CD4
+ cells
between ages 2 to 12 years was calculated to be 0.34% per year
while for SPNT this was at 0.4% per year. From early teens until
30 years rates dropped to 0.11% proliferating CD4
+ cells per year
for both anti-Ply and anti-SPNT responses. Anti-influenza
responses showed a similar trend but at a higher intensity at all
the age groups analysed. Interestingly, when we assessed the results
of a separate study analysing the age-associated rates of
community-acquired pneumonia (CAP) which is primarily due
to S. pneumoniae infection, in the UK between 2000 to 2003 [21],
we observed that the combined proliferative responses of CD4 T
cells to SPNT and Ply showed an inverse relationship to the levels
of CAP (Figure 2b, generated with permission from P.R. Myles).
This finding suggests a potential role for the cell mediated anti-
pneumococcal response in protecting from disease.
Anti-pneumococcal responses by mucosal CD4 cells are
regulated by CD25
hi Treg cells
T regulatory cells are increasingly being recognised as
important modulators of responses to bacteria and viruses [22–
26]. Interestingly, animal studies have revealed that the presence
of commensal bacteria can induce Treg levels in vivo [27], and
similarly, we have established that Treg appear during the
acquisition of natural immunity to Neisseria (N.) meningitidis, another
upper respiratory tract coloniser [20]. Tregs can have unfavour-
able effects on host immunity by preventing the generation of
effective immune responses. For example in humans, elevated
Treg numbers are associated with chronic viral infections such as
hepatitis B and HIV with the depletion of these cells in vitro
resulting in improved T cell responses [28,29]. We therefore
assessed the role of Tregs on the mucosal anti-pneumococcal
responses by CD4+ T cells [30,31]. Previous works have shown
that many, although not all populations of Tregs can express the
IL-2 receptor subunit CD25 at high levels [22–25]. We therefore
investigated whether pneumococcus-specific Treg cells are present
in the tonsils by depleting the Treg cell containing CD25
hi cell
population from cultures of tonsil mononuclear cells (MNC) in
order to assess the impact of such cells on mucosal anti-
pneumococcal CD4 T cell responses. We found a significant
increase in the proliferative responses of tonsil CD4
+ T cells to Ply
(Figure 3a) and SPNT (Figure 3b) after CD25 depletion in the
majority of subjects at the age of 17 years and above but not for
those below 17 years. As was observed previously [20], analysis of
the CD4 cell anti-influenza responses revealed no significant effect
of CD25
hi cell depletion on the level of proliferative responses to
influenza (Figure 3c).
In order to confirm that the enhanced proliferation observed
following the depletion of CD25
hi cells was as a result of this
population exerting an inhibitory effect in undepleted cultures, we
subsequently added back the CD25
hi cell fraction to the depleted
MNC population at the original proportion and at three times the
Author Summary
The S. pneumoniae bacteria is a major cause of disease (e.g.
pneumonia and meningitis) particularly affecting infants.
In most cases bacteria can colonise the nose without
causing harm, however colonisation is thought to be a
prerequisite of disease. With increasing age colonization
and disease, rates gradually decrease which is likely due to
the development of immunity to the pneumococcus with
age. The CD4 T cells of the immune system may contribute
to the defence against bacterial colonisation by producing
factors that promote pneumococcal killing. Herein, we
show that CD4 T cells reactive to pneumococci are found
in greater numbers at the site of colonisation and
gradually increase in their levels from infancy. However,
at the peak of CD4 T cell responses from late teens, we
detected the presence of regulatory T cells (Tregs) which
suppressed anti-pneumococci CD4 T cell activity greatly.
Our finding shows that pneumococcal reactive CD4 T cells
selectively populate colonisation sites and increase with
age as a result of ongoing bacterial exposure throughout
life, inversely correlating with colonisation and disease
rates. As factors that utilise CD4 T cells become
increasingly advocated as potential preventative strategies
against pneumococcal carriage and disease, the observed
effect of Tregs must be considered.
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showing notable increased CD4
+ T cell proliferation to pneumo-
coccus post Treg depletion revealed that restoration of CD25
hi cell
numbers resulted in the reversal of the observed increased
proliferative responses to Ply (Figure 4a) in subjects above the
age of 17 years. When CD25
hi cells were added back at three times
the original percentage, the proliferative responses decreased even
further. When subjects below the age of 17 years were assessed
(Figure 4b), no notable changes in the proliferative response were
observed between the undepleted, CD25
hi depleted, CD25
hi
added back cell cultures. In keeping with the lack of effect of
CD25
hi cell depletion on influenza specific CD4
+ cell responses,
no significant change in the proliferative response to influenza
were observed following the removal of, or the addition back of
this population to depleted MNC populations, even at three times
their normal frequency (Figure 4c). Collectively, these data reveal
that Treg cells are present within mucosal lymphoid tissues of
adults and are able to significantly suppress the proliferative
responses of CD4
+ T cells to S. pneumoniae.
Mucosal T cell immunity to S. pneumoniae is dominated
by Th1 and Th17 responses
CD4 T cells produce and secrete a variety of cytokines that
control and co-ordinate effector mechanisms involved in
pathogen clearance. In order to determine the nature of the
anti-pneumococcal immune response in the mucosa, we
assessed cytokine production in supernatants taken from
cultures of palatine tonsil MNC following in vitro stimulation
with Ply. We observed significant production of TNF-a,I L - 2
and IL-10 (p ,0.05) and a modest but not significant increase
in IL-17 (p=0.06) compared to the levels observed in
unstimulated cultures (Figure 5a). In order to confirm the
cellular origin of the pneumococcal antigen-mediated cytokine
production, we performed similar studies using intracellular
cytokine staining in combination with staining for CD4
receptor. Flow cytometric analysis after 6 to 7 days stimulation
and then an overnight re-stimulation with Ply revealed
significant increases in CD4 T cell IFN-c,T N F - a and IL-17
(Figure 5b).
Figure 1. Anti-pneumococcal CD4 T cells proliferative responses in adult tonsils and blood during in vitro pneumococcal peptide
antigen challenge. (a) A typical FACS plot for CFSE staining within CD4
+ cells post simulation with flu or SPNT compared to unstimulated (media
alone) cells. (b) Purified tonsil MNCs (n=8) were stimulated over 9 days with flu or recombinant Ply peptides, or D39 bacterial SPNT or media. CD4
+
cells identified by FACS staining were assessed for their proliferative responses by CFSE staining. Percent of proliferating CD4
+ cells post flu, Ply or
SPNT stimulation were all significantly higher than media control (* =p ,0.05). (c) Greater proliferative responses to pneumococcal peptides by
tonsil compared to blood CD4
+ cells. Tonsil MNCs and PBMCs from the same individuals (n=5), were purified and stimulated in vitro with flu, Ply or
SPNT and CD4
+ cell proliferation assessed after 9 days. No significant difference was observed between tonsil (open bars) and blood (filled bars) CD4
+
responses to flu but were significant to SPNT (* = p ,0.05) and almost significant (# = p 0.06) for Ply. Values were calculated with the background
(i.e. media alone) proliferation subtracted. Error bars show the SEM.
doi:10.1371/journal.ppat.1002396.g001
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is modified by Treg-mediated suppression, we then analysed
cytokine production following the removal of the Treg containing
CD25
hi cell population from the tonsil MNC cultures pre
pneumococcal challenge. Intracellular flow cytometric analysis
revealed increases in IFN-c and IL-17 positive cell numbers in the
Treg depleted cell cultures. As expected, analysis of those few
subjects not displaying increases in anti-pneumococcal CD4
proliferation post Treg depletion revealed little change in their
IFN-c and IL-17 expressing CD4 T cell numbers following
CD25
hi cell depletion (data not shown). The results indicate an
inhibitory effect of Tregs on the pneumococcal-induced produc-
tion of these specific cytokines by mucosal CD4 T cells. No
significant effect on TNF-a and IL-10 production was observed
following the depletion of CD25
hi cells.
Cell surface CTLA-4 and PDL-1 molecules are involved in
the inhibition of anti-pneumococcal CD4 T cell
proliferation by Tregs
Initial transwell experiments indicated the involvement of cell
contact-dependent mechanism/s for the observed Treg suppres-
sion of CD4 T cell proliferation (data not shown). We therefore
assessed whether Tregs utilised the inhibitory cell surface
molecules CTLA-4 and PDL-1 [29,32–37] during their suppres-
sion of anti-pneumococcal responses by tonsil CD4
+ T cells. This
was achieved by pre-blocking purified CD25
hi Tregs with
neutralizing antibodies prior to addition back into CD25
hi
depleted cell population and subsequent 8 days in vitro culture in
the presence of SPNT. Flow cytometric analysis revealed that
approximately 80% of CD4
+ CD25
hi Tregs were successfully
bound by the antibodies while up to 2% of non Tregs cells in the
culture became bound by the neutralizing antibodies during the
entire 8 day culture period (data not shown) indicating blocking
was specific to the Treg cell population. Blocking with CTLA-4
antibody but not an isotype matched IgG1 antibody control
resulted in a significant increase in the mean percentage CD4
proliferation from the undepleted culture (Figure 6a). Just as
depletion of CD25
hi cells resulted in a significant increase
(p ,0.05) in the mean percentage of CD4 T cell proliferation,
pre-blocking with PDL-1 but not the isotype matched control
IgG2 antibody on CD25
hi cells and their subsequent restoration
back into CD25
hi depleted cell populations also resulted in
significant increase (p ,0.05) in mean CD4 cell proliferation
(Figure 6b). Collectively, these data suggests that the suppression of
mucosal anti-pneumococcal T cells by Treg involves surface
interactions via CTLA-4 and PDL-1 inhibitory co-receptors.
Blocking either CTLA-4 or PDL-1 did not increase proliferative
responses up to the levels observed in post CD25
+ cell depletion
indicating additional mechanisms may also be involved for Treg
suppression of anti-pneumococcal CD4 T cell responses.
Detection of anti-pneumococcal Ply Treg cells in mucosal
tissue
MHCII tetramers consisting of four identical biotinylated
MHCII molecules presenting an epitope of a specific antigen,
ligated to one another via fluorescently labelled strepavidin
molecules have been increasingly utilised to allow the flow
cytometric detection and quantification of CD4 T cells with
specificity to the antigen being presented. The target CD4 T cells
bind to the antigenic epitope/tetramer complex via their surface T
cell receptors (TCR) thus allowing their subsequent detection [38].
We therefore utilised this technology in order to determine
Figure 2. Mucosal CD4 T cell responses to pneumococci during aging and its relation with CAP rates. (a) Mucosal CD4 T cell responses
to pneumococcal peptide antigen display gradual age-related increases from early childhood until mid-20’s and remain relatively constant until mid-
life. Tonsil MNCs from subjects (n=80) between the ages of 2 to 39 years and grouped into five age groups were assessed for their CD4 T cell
proliferative responses to Strep. Pneumoniae Ply (circles, solid grey line of best fit), SPNT (square, dashed black line of best fit) and flu (triangle, black
line of best fit) peptides, error bars show SEM. (b) Graph for data observed by Myles et al showing the trend (black crosses, dashed black line of best
fit) of incidence rates of CAP per person/year in the UK at different age groups between 1991-2003 (n=56332, R
2=0.97) in relation to the trend (grey
circles, solid grey line of best fit) of mean total (to Ply and to SPNT) anti-pneumococcal CD4 T cell proliferative responses between the ages of 2 to 39
years old (R
2=0.93). Graph for CAP data was generated with permission from P.R. Myles.
doi:10.1371/journal.ppat.1002396.g002
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+ Tregs which we observed to inhibit CD4 T cell
proliferative responses to Ply can be detected within tonsillar
MNC populations. Using Ply epitope presenting MHCII tetramers
we confirmed the presence of S. pneumoniae specific Treg cells
within the tonsil CD25
+ cell population of adults by generating
phycoerythrin (PE)-labelled HLADR04 tetramers bound to one of
three different Ply peptide epitopes, or to a non-epitope peptide
from Ply as a tetramer-Ply epitope negative control, which was
observed to bind poorly to Ply specific cell lines we had generated
(data not shown). The HLADR0401 MHCII molecule was chosen
as a large fraction of the Caucasian population expressed this
particular serotype, thus increasing the chances of finding suitable
HLADR0401 subjects for subsequent tetramer analysis. Tetramer
binding was assessed on tonsil CD25 enriched cells by flow
cytometry (Figure 7). Cells were stained with streptavidin-PE alone
(Figure 7a), the tetramer-Ply negative control (Figure 7b), or three
tetramer-Ply epitope cocktail (Figure 7c). Approximately 45% of
CD25 enriched CD4
+ cells were found to be FoxP3
+/CD127
low/-
Treg cells. Within this population 0.01% of cells bound to
streptavidin PE alone and 0.47% bound to the control tetramer.
Importantly, 1.96% of the Treg bound to the Ply epitope
tetramers. In five individuals over 17 years old assessed, 0.53 to
1.96% (with % of cells binding to streptavidin-PE control
subtracted) of Treg cells were Ply-specific, which was significantly
greater (p ,0.05) than the 0.005 to 0.46% (with % of cells binding
to streptavidin-PE control subtracted) of Treg cells bound by the
negative control Ply tetramer. Similar assessment of blood Treg
population indicated lower frequencies of Ply specific Treg cells as
indicated by a lack of tetramer staining (mean 0.02%) of CD4
+
FoxP3
+/CD127
low/- peripheral blood mononuclear cells (Figure 8).
This result would therefore indicate a similar sequestration of
pneumococcal specific Treg cells within the tonsils as that
Figure 3. Inhibitory action of anti-pneumococcal responses by regulatory T cells. Inhibition of mucosal CD4
+ T cell anti-pneumococcal
responses to Ply (a) and SPNT (b) but not to flu (c) by CD25
hi regulatory T cells in subjects above 16 years old as indicated by increased cell
proliferation following depletion of CD25
hi cells from tonsil MNC population is observed. Subjects (n=50) were grouped into those aged less than
17 yrs, 17 to 25 yrs and .25 yrs. Individual subject’s proliferative response pre and post CD25
hi cell depletion are shown with a connecting dashed
grey line, while solid black bars and black dashed line represent mean proliferative values for undepleted and CD25
hi cell depleted populations. (* =p
,0.05).
doi:10.1371/journal.ppat.1002396.g003
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cells, and also implies that the low CD4 T cell responses in
blood is not due to a high frequency of anti-pneumococcal Tregs
residing within this compartment and suppressing immunity.
Thus using these novel tools we have shown the presence of
tonsil FoxP3
+/CD127
low/-, CD25 enriched CD4
+ Treg cells that
are specific for pneumococcal Ply antigen, likely contributing
to the observed suppression of anti-pneumococcal CD4 T cell
responses.
Discussion
In the current study, the magnitude of CD4 T cell response to S.
pneumoniae with age was assessed in view of the reported age-related
decline in pneumococcal disease and the proposed involvement of
cell mediated immunity to this acquisition of protection from
disease. We hypothesised that assessment of CD4 T cells residing
within upper respiratory tract mucosal lymphoid tissues that are in
close proximity to the site of S. pneumoniae colonization may prove
Figure 4. Effect of restoration/addition of Tregs (CD25
hi) cells back into CD25
hi cell depleted MNC samples on proliferative
responses by pneumococcal specific CD4
+ T cells. Tonsil MNCs were depleted of CD25
hi cells and left or CD25
hi cells added back at the original
proportion (,10%) or at three fold the original proportion (i.e. 30%). Cells were obtained from individuals (a) .16years (n=5) and stimulated with
SPNT, (b) ,17 years (n=3) and stimulated with SPNT or individuals (c) .16 years and stimulated with flu (n=5). Percentage of proliferating CD4
+
cells are shown for each individual (open circles) as well as mean (black bars) proliferation in undepleted or CD25
hi depleted or CD25
hi depleted with
CD25
hi added back at the original proportion or CD25
hi depleted with CD25
hi added back at three times the original proportion. (* =p ,0.05).
doi:10.1371/journal.ppat.1002396.g004
Figure 5. Cytokine profile of tonsil MNCs following S. pneumoniae antigen stimulation. Cytokine (IL-10, IFNc, TNFa, IL-2 and IL-17)
production by tonsil MNCs following stimulation with Ply (grey bars, SEM are shown by error bars)) was assessed by quantifying cytokine levels in cell
culture supernatants (n=8) at 7 days post cell stimulation by Luminex assay. Mean values are shown for each subject’s cytokine levels post Ply
stimulation with background cytokine levels in media alone subtracted, individuals with ,7% proliferating CD4
+ cells post Ply stimulation were not
assessed (a). Cytokine producing CD4
+ cells were analysed by intracellular cytokine FACS analysis for (IL-10, IFNc, TNFa and IL-17) to determine
cytokine production specifically by CD4
+ cells post Ply stimulation (n=10). Filled bars show mean percentage of cytokine expressing CD4
+ cells with
the background (media alone) percentage values subtracted (b). Cytokine production by CD4
+ cells post Ply stimulation in undepleted (open bars)
and CD25
hi cell depleted (filled bars) tonsil MNCs (n=13) was compared by intracellular FACS analysis. Similarly, values represent the mean percent of
CD4
+ cells that are expressing cytokine, with the background (media alone) values subtracted. Only the subjects showing .5% increased
proliferation post CD25
hi cell depletion were assessed (c). All error bars represent SEM (* =p ,0.05 and # =p 0.06).
doi:10.1371/journal.ppat.1002396.g005
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pneumococcal responses by CD4 T cells from blood and palatine
tonsils revealed a greater level of responsiveness by the cells
obtained from the latter source. Although, it must be acknowl-
edged that tonsils are only available from individuals who have
either an upper airway obstruction or have suffered from recurrent
tonsillitis, the results are highly suggestive of increased numbers of
pneumococcal specific CD4
+ T cells within lymphoid tissues in the
vicinity of the nasopharynx, which we propose to be likely due to
the sequestration of these cells within these organs. The
containment of these cells within the upper respiratory tract
would likely prove advantageous in promoting more efficient
immune responses by increasing the likelihood for antigenic
encounter and consequently facilitating more rapid, localised
responses. Results from a previous study had indicated higher anti-
pneumococcal responses by tonsil compared to blood CD4 T cells
but failed to determine whether such a difference was significant
[13]. Herein, we show that this is indeed the case.
Assessment of the pneumococcal-specific responses by mucosal
CD4 T cells with age revealed a gradual age-related increase in the
magnitude of cellular proliferation from the youngest age assessed
at 2 years old until the age of approximately 20 years. Cytokine
analysis revealed Th1 and Th17 type anti-pneumococcal CD4 T
cell responses were most evident, suggesting the recruitment and
activation of macrophage and neutrophils as a primary inductive
mechanism for protection by CD4 T cells from pneumococcal
carriage and disease, as observed in mouse models [11,14]. We
hypothesise that the progressive rise in CD4 T cell responses with
age may be at least partially responsible for the observed decline in
pneumococcal disease rates through childhood and early adult-
hood. Support for this proposal comes from epidemiological
investigations into CAP. Epidemiological studies of CAP cases in
Finland and earlier in the US found the incidence of the disease to
show greatest decline during the first 14 years of life [39,40]. This
was also supported by a more recent investigation in the UK,
which reported incidence rates dropping from 20 cases/10000
inhabitants to 6 cases/10000 inhabitants per year (Figure 2b). The
incidence of CAP dropped more slowly by a further 15% between
the ages of 15 to 29 years [21]. Thus, an inverse relationship
between CAP and CD4 T cell responses can be observed, with the
graph for the rates of CAP appearing to be almost a mirror image
of the graph for the rate of CD4
+ T cell proliferative responses to
pneumococcus with increasing age. While this is suggestive of a
role for mucosal CD4
+ T cell responses in reducing CAP
incidence, a role for other factors cannot be dismissed.
Furthermore, whether the role of the CD4
+ T cell response is
mediated directly or via help for antibody production is unclear.
Data from studies conducted by Laine et al on Kenyan subjects
revealed increases in IgG and IgA to Ply as well as pneumococcal
surface protein A (PspA) up to the age of 3 to 5 years which then
plateau at least until 20 years [41]. These findings would indicate a
contributory role for the antibody response in reducing pneumo-
coccal disease early on in life but less so after 5 years of age when
such responses plateau despite CAP levels still continuing to
decline until teenage years. Thus, from the age of six years it is
tempting to speculate that the CD4 T cell response is perhaps of
Figure 6. Effect of blockage of CTLA-4 and PDL-1 on CD25
hi cells their suppression of anti-pneumococcal proliferative responses by
CD4
+ cells. Purified CD25
hi cells were preblocked with anti-human CTLA-4 or anti-human PDL-1 blocking antibodies or isotype control (IgG)
antibodies and added back to CD25
hi depleted MNCs (i.e. CD25
- cells) at the same original proportion and then stimulated with SPNT over 8 days and
CD4
+ cells proliferation analysed. Graph shows the mean percentage of proliferating CD4
+ cells post SPNT stimulation in the anti-human CTLA-4 (a)o r
anti-human PDL-1 preblocked CD25
hi cells (b) groups (n=5 each group). (* =p ,0.05).
doi:10.1371/journal.ppat.1002396.g006
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despite disease rates continuing to drop. Additional analysis of
antibody responses, and in particular detailed characterisation of
the levels and functional properties of both systemic and mucosal
responses would be helpful in understanding the relative roles.
Murine and studies in human childhood have shown an important
role of CD4 T cells, particularly Th17 cells in inhibiting
pneumococcal carriage lending support to a correlation between
the cell-mediated response to pneumococcus and carriage rates of
the bacteria [12–14]. Despite decreasing disease and carriage
rates, CD4 T cell responses were observed to increase with age, we
propose that multiple exposure events to S. pneumoniae takes place
throughout life in order to maintain and, for the time period
assessed in this study progressively augment the anti-pneumococ-
cal CD4 T cell responses with age.
Mucosal T cell immune responses are commonly susceptible to
the suppressive actions of Treg cells, and herein for the first time,
we observed this to be also the case with adult human anti-
pneumococcal CD4 T cell responses. Interestingly a significant
Treg effect was observed during the ages when relatively strong
anti-pneumococcal CD4 T cell responses have developed. Such
regulation may be useful at this stage of life when these more
robust responses may have a greater likelihood to cause bystander
damage to host tissues following an immune response to
pneumococci. Furthermore, strong responses to colonizing
pneumococcus may lead to the damage of mucosal cell walls
and permit bacterial penetration into tissues resulting in infection
and disease. Indeed, recent studies in mice have observed the
ability of gut commensal bacteria to induce the generation of Treg
cells within the mucosal tissue in order to inhibit inflammatory
responses that can cause immunopathology and lead to autoim-
mune disease [42,43]. With the use of novel pneumococcal specific
tetramers bound to epitopes of Ply, we were able to confirm the
presence of Treg cells specific for pneumococcal Ply in tonsillar
populations. It is therefore likely that these cells, as well as Treg
which may recognise and respond to other pneumococcal
antigens, are involved in the observed suppression of CD4 T cell
responses to pneumococcus. Within mucosal lymphoid tissue
we observed that at least 1 per approximately 200 FoxP3
+/
CD127
low/- CD4
+ Treg cells in the tonsil were specific for Ply.
This high incidence may reflect a level of specific induction at, or
retention of anti-pneumococcal Treg cells within this site. Impor-
tantly the frequency of such cells in the peripheral blood was much
lower. In future studies the novel Ply presenting tetramers that we
have generated would be invaluable tools in enabling a com-
parison of the anti-Ply CD4 T cells in each compartment.
The reason for the delay in the development of Treg responses
with age is unclear. We hypothesise that this may be a
Figure 7. Detection of Ply specific CD127
low/- FoxP3
+ CD4
+ Treg cells in CD25 enriched tonsil and blood MNC. CD25 enriched MNC
were stained with anti- CD127 and anti FoxP3 to allow identification of Tregs and with (a) strepavidin-PE, (b) negative control Ply tetramer-PE and (c)
Ply tetramer-PE and analysed by FACS. A typical example of a FACS plot is shown. While the CD127
low/- FoxP3
+ CD4
+ Treg cells show low level
staining at 0.0% with strepavidn-PE (a) and negative control Ply-tetramer at 0.05% (b), a significantly higher percentage of Treg cells are bound by
Ply-tetramers at 1.96%(c).
doi:10.1371/journal.ppat.1002396.g007
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host and the pneumococcus. It is possible that, during childhood,
the greater propensity for colonisation events to become associated
with infection favours the development of responses lacking T cell
regulation. However, as immune responses increase with age,
infection becomes rarer and the balance shifts toward carriage
without invasion, which might subsequently predispose to the
development of regulation. Alternatively, this observation may be
due to differing carriage rates of the bacteria during aging.
Support for this comes from our previous study assessing the CD4
T cell response to N. meningitidis (MenB) which like that of S.
pneumoniae also became subject to Treg cell suppression [20].
Unlike in S. pneumoniae however, Treg suppression of MenB
responses became evident earlier on in life between 8–11 years of
age. While carriage rates are highest for S. pneumoniae during
approximately the first decade of life and dropping to just below
10% by mid-teens onwards, for MenB carriage does not reach
peak levels until late teens with pre-teens prevalence rates
remaining below 10% [44,45]. Thus, with regulation for the two
bacteria appearing at ages when carriage rates for both are also
similar (i.e. at just below 10%), it is tempting to speculate for the
role of carriage in the development of a regulatory mechanism. A
recent study by Zhang et al suggested that the adenoids of young
children who were colonised, but not those who were not
colonised with S. pneumoniae, contained Treg that could suppress
anti-pneumococcal T cell responses [46]. Although they were not
able to confirm that the Treg that they studied were pneumococ-
cus specific as opposed to being activated polyclonally to factors
such as TLR ligands in the preparations or identify the
mechanisms utilised by the Tregs for suppression, their findings
do support a possible role for colonization in the development of
regulation. We did not distinguish between carriers and non-
carriers in our studies and accordingly did not see evidence of Treg
controlling reactivity in such young children. While Zhang et al’s
findings suggests a direct correlation between colonisation and
Treg suppression of anti-pneumococcal CD4 T cells in infants, the
presence of Tregs despite the observed low levels of colonisation in
adults [12,14] would indicate that pneumococcal-specific Treg
become a stable part of the repertoire with age. Transient Treg
responses in children may promote colonisation and therefore be
undesirable. In adults, where colonisation is less frequent, they
may have a different role altogether; to dampen potentially
pathological immune responses during pneumococcal exposure
and promote a beneficial profile of immunity at the mucosa.
Although the case for the majority, not all subjects above the
age of 16 years displayed Treg inhibition of their anti-
pneumococcal CD4 T cell immune responses, with some even
showing decreases in responses following depletion of CD25
hi cells.
Such variation is almost inevitable in complex human systems, and
may possibly be due to differences in bacterial carriage and/or
differences in the number of S. pneumoniae exposures throughout
life, as well as other factors affecting the state of the local immune
system at the time of the study. For example, in individuals with an
ongoing mucosal response effector cells as well as Treg cells may
Figure 8. Frequencies of Ply specific Tregs in the tonsil compared to blood. CD127
low/- FoxP3
+ CD4
+ Treg cells in CD25 enriched blood and
tonsil MNC populations were stained with Ply tetramer-PE and assessed by FACS for percentages of Treg cells specific for Ply in the two
compartments. Graph shows the mean % of Tregs bound by Ply tetramer in blood (black bars) and in tonsils (grey bars) with % of Tregs stained with
control tetramer subtracted (n=3 for blood group and =5 for tonsil group).
doi:10.1371/journal.ppat.1002396.g008
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pool as well as those potentially capable of controlling prolifera-
tion.
The Treg cells observed in our study mediated suppression
using the inhibitory cell surface molecules CTLA-4 and PDL-1 in
this process. CTLA-4 on Treg cells may inhibit pneumococcal
specific responses by preventing and downregulating cell co-
stimulation via B7.1/B7.2 and CD28 interactions between antigen
presenting cells and effector T cells respectively [33,47]. Treg cells
may utilise PDL-1 in their suppression by engaging programmed
death 1 (PD1) and/or B7.1 on effector T cells to attenuate T cell
receptor (TCR) signalling, partly by upregulating the T cell
inhibitory basic leucine transcription factor (BATF) in order to
suppress T cell activation and cytokine production [48,49]. It is
interesting to note that both CTLA-4 and PDL-1 can bind B7.1 in
light of a previous study observing the capacity for Treg cells to
induce their inhibition through engagement of B7 molecules
expressed on their target T cells [50].
The role of the antibody response in host defence against
pneumococcal disease has been extensively documented, and it is
therefore interesting to consider whether the Treg characterised
here may affect these responses directly or indirectly via their
control of effector T cells. Interestingly, studies in mice and human
have indicated a capacity of Tregs to affect antibody production
both in vitro and in mice in vivo. In mice increases in IgG and IgA in
mucosal tissues and mucosal secretions have been observed as well
as decreases in splenic IgG and IgM in the presence of Tregs
[51,52]. While in humans, Tregs were observed to inhibit IgG,
IgM, IgE and IgA production by tonsillar B cells following their
polyclonal activation [53]. Thus a possible additional effect of the
pneumococcal specific Tregs that we have observed in this study
on B cell responses to S. pneumoniae along with the CD4 T cell
response merits assessment.
Several mouse studies have shown the importance of the Th17
CD4 response in inducing neutrophil and monocytes/macrophage
mediated clearance of colonizing bacteria. Studies by Lu et al and
Mureithi et al have observed in vitro IL-17 production following
challenge with pneumococcal antigens with Lu et al showing an
enhancing effect of IL-17 on the phagocytic killing of pneumococci
by human neutrophil cells [14,15]. Our assessment of cytokine
production by adult mucosal CD4 T cells post-pneumococcal
antigen challenge also revealed increases in IL-17 levels. Such
Th17 responses may limit colonization in this age group and since
colonization is a prerequisite of disease, may consequently
contribute to the lower disease rates observed in human adults
[4,45]. However, our data additionally revealed that Tregs were
able to significantly decrease the observed IL-17 production by
anti-pneumococcal CD4 T cells, which have not yet been shown
previously. The ability of Treg cells to preferentially block not only
IL-17 but also IFN-c pro-inflammatory cytokine production is
interesting as this may reveal a role for these cells in blocking
unwanted inflammation induced pathology at the mucosa upon
contact with colonizing S. pneumoniae. Coincidently, neutrophils
and macrophages, the main protagonist cell populations involved
in protecting against pneumococcal carriage and/or disease are
found to be principally mediated by these two particular cytokines
[14,15], thus providing a possible motive for the preferential effect
of Tregs on their production. Other previous studies have shown
the capacity for Tregs to inhibit Th17 cell responses as we have
observed herein [54,55]. It is possible that the Treg responses
observed serve to moderate potentially pathological immunity at
the mucosa in order to maintain a balance between the need to
contend with a potentially harmful pathogen and to preserve
physiological and barrier function. Whilst regulation may be
evolutionary advantageous in the context of commensalism, the
potential to suppress protective immunity during pneumococcal
invasion may conversely facilitate disease.
Our findings have clear implications for the development of
vaccines against the pneumococcus. As we move from approaches
targeted solely at stimulating antibody responses to polysaccharide
antigens and toward the generation of protein based pneumococ-
cal vaccines, it will be important to consider the extent to which
new approaches mimic natural immunity in providing local
protection at the mucosa. Further, it will be important to recognise
that vaccines that drive potent Th1 and/or Th17 responses
without inducing the balancing effects of Treg could potentially
lead to enhanced pathological outcomes in disease, and even
during colonisation. The challenge in vaccinating adults will be to
enhance the pre-existing responses that we have described as
immunity wanes in the elderly, while maintaining the fine balances
that mediate protection. As may be the case in other infectious
diseases, vaccines should not necessarily be produced with the sole
aim of stimulating as strong an immune response as is possible, but
should rather be targeted at modulating immunity to achieve the
desired outcome.
Materials and Methods
Ethics statement
Palatine tonsils and blood samples were obtained from
otherwise healthy individuals (aged 2 to 39 years) undergoing
routine tonsillectomy for recurrent tonsillitis or upper airway
obstruction at Bristol Royal Hospital for Children, Southmead
Hospital or Saint Michael’s Hospital in Bristol, United Kingdom.
Tonsils were collected into HBSS media (Invitrogen) supplement-
ed with 100 U/ml penicillin, 100 mg/ml streptomycin (Sigma) and
blood samples into citrate phosphate dextrose solution (Sigma).
Patients with immunodeficiency or serious infections were
excluded from the study. Participants with inflamed tonsils at
the time of surgery were not recruited. No participants had
received pneumococcal vaccine. The study was approved by, and
sample collection and research were undertaken in accordance
with the guidelines set out by the South Bristol local research ethics
committee (reference number; E4388). Written informed consent
was obtained from all participants and/or their legal guardians.
Antigens
Pneumococcal cell culture supernatants (SPNT) from a standard
encapsulated type 2 (D39) S. pneumoniae strain (National Collection
of Type Cultures, NCTC #7466) was prepared as described
previously [56] and used at a concentration of 2 mg/ml for cell
stimulations; the optimal level as determined in dose response
studies (data not shown). Recombinant Ply, a Ply protein with a
Trp433-Phe mutation that reduces its haemolytic activity without
affecting antigenicity generated as previously described [19], was
added at a concentration of 0.1 mg/ml for cell stimulations.
Pneumococcal antigens were tested for the presence of contam-
inating Gram-negative endotoxin using the colorimetric LAL
assay (KQCL-BioWhittaker, Lonza). All purified proteins had
endotoxin levels at concentrations that were too low to have any
notable effect on CD4 T cell responses (,0.6 units per microgram
of protein). Fluzone 2002–2003 formula inactivated split-virion
influenza (flu) vaccine (Sanofi-Pasteur MSD) was used at 0.09 mg/
ml hemagglutinin.
Mononuclear cell isolation and CD25
hi cell depletion
Blood and tonsil tissue (MNC) were isolated by histopaque
density gradient separation as described previously [20]. CD25
hi
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8 MNC using anti-human
CD25 coated MACS microbeads (Miltenyi Biotec) and magnetic
cell sorting (MACS) on LD columns (Miltenyi Biotec) according to
the manufacturer’s instructions. Purity of depleted cells were
typically .96% as assessed by flow cytometry using APC labelled
anti-human CD25 antibody (BD Pharmingen). Approximately 8–
10% of tonsil lymphocytes were found to be CD25
hi.
Cells were resuspended at 0.8610
6/ml in RPMI 1640 media
containing 2% human serum (Sigma), 2 mmol L-glutamine
(Sigma), 100 U/ml penicillin (Sigma) and 100 mg/ml streptomycin
(Sigma). Cells were plated at 1 ml/well in 48 well plates (Corning)
and stimulated with flu, pneumococcal supernatant or Todd
Hewitt Broth (negative control), Ply or left unstimulated as
negative control for up to 9 days, at 37uC/5%CO2. In some
stimulation experiments the cell culture supernatants were
collected 5 days post stimulation and stored at 270uC for
subsequent cytokine assessment. Cells were subsequently analysed
for cell proliferation.
For the CD25
hi add back experiments, MACS purified CD25
hi
cells were added to 0.8610
6 CD25
hi depleted cells per ml media at
the original (8610
4 i.e. 10%) or 3 times the original (i.e. 2.4610
5)
CD25
hi cell proportion in undepleted MNC.
CD4+ T cell proliferation assay
Prior to stimulation, cells were labelled with CFSE dye
(Invitrogen) according to the manufacturer’s instructions, in order
to permit flow cytometric tracking of cell division. Cells were
stained with anti-human CD4- phycoerythrin (PE)-Cy7 antibody
(BD Pharmingen) for 30 mins at 4uC and then with the vital dye
TOPRO3 (Invitrogen), according to the manufacturer’s instruc-
tions just prior to flow cytometric (FACS) analysis. Cells were
analysed using FACS Canto (Becton Dickinson) acquiring 20000
lymphocytes (gated according to forward and side scatters). FACS
results were subsequently analysed with FlowJo (TreeStar). The
identification of cells that have undergone cellular division and the
gating of FACS dot plots according to CFSE staining was
performed as described previously [13] and consequently
background (i.e. media alone for Ply stimulated or Todd-Hewitt
broth treated for SPNT stimulated) proliferation were subtracted
from values of stimulated cells. Dead cells (i.e. cells stained with
TOPRO3) were excluded from the flow cytometric analysis. Our
studies have shown that the data obtained with this technique,
which allows identification of the dividing cells, directly correlates
with that obtained from
3H-thymidine incorporation experiments
from matched samples (data not shown).
Cytokine measurement
IL- 2, 5, 10, 17, TNF-a and IFN-c levels in the cell culture
supernatants were quantified 7 days post stimulation with Ply by
Luminex xMAP technology for cytokine quantification and
Luminex 200 exponent system (Luminex) according to the
manufacturer’s instructions. Additionally IL-10, -17, TNF-a and
IFN-c production by CD4
+ T cells was measured by intracellular
cytokine flow cytometric analysis. Briefly, at day 6 to 7 of culture,
cells were restimulated for 12 hours with Ply antigen and BD
Golgi Stop protein transport inhibitor (BD Bioscience) was added
for the last 8 hours. Cells were stained with Live/Dead near IR
Stain kit (Invitrogen) according to the manufacturer’s instructions,
in order to exclude dead cells from flow cytometric analysis and
then with anti-human CD4-V450 (BD Pharmingen). Cells were
fixed and permeabilized using BD cytofix/cytoperm kit (BD
Biosciences) according to manufacturer’s instructions and were
subsequently stained with antibodies to TNFa-alexa flour 700 (BD
Pharmingen) and IL-10-APC (BD Pharmingen) or IL-17- alexa
flour 700 (BD Pharmingen) and IFNc-APC (BD Pharmingen) at
4uC for 30 mins and analysed with the BD LSR flow cytometer
(Becton Dickinson). The percentage of cells positively staining for
cytokines in unstimulated samples were subtracted from the
percentage of positively cytokine stained cells in the stimulated
samples.
CTLA-4 and PDL-1 blocking
For pre-blocking experiment, 5610
6 CD25
hi CFSE stained cells
obtained during CD25
hi depletion by magnetic cell sorting on LD
columns as mentioned above in 1 ml RPMI 1640 media
containing 1% human serum, 2 mmol L-glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin were treated with 5 mg/ml
anti-human CTLA-4 (eBoscience) or 15 mg/ml anti-human PDL-
1 (eBoscience) or appropriate isotype-matched antibody controls
(eBoscience) and incubated for 3 hours at 37uC/5%CO2. Cells
were extensively washed and added back to CFSE stained CD25
hi
depleted cell fraction at a ratio of 1:10. Flow cytometric analysis
revealed .80% of the CD25
hi cells to be successfully blocked.
Cells were stimulated with antigens and left for up to 8 days in
culture at 37uC/5%CO2 and then analysed for cellular prolifer-
ation by CFSE staining.
Generation of tetramers
Biotinylated HLADR0401 MHCII tetramers bound to strepta-
vidin-PE were generated at the Benaroya Research Institute
(Seattle, USA). Four different Ply 13mer peptide epitopes (P1;
SerAspIleSerValThrAlaThrAsnAspSerArgLeu, P2; ArgProLeu-
ValTyrIleSerSerValAlaTyrGlyArg, P3;ValTyrLeuLysLeuGluThr-
ThrSerLysSerAspGlu,P4;ThrSerPheLeuArgAspAsnValValAlaThr-
PheGln) were identified from the complete Ply protein amino acid
sequence by using TEPITOPE (Vaccinome) [57]. Each Ply epitope
was tested for its capacity to induce proliferation of Ply-specific T cell
lines in order to determine the potential applicability of the epitopes
for detecting CD4 T cells. Tetramers were generated by loading the
Ply peptides onto empty biotinylated DR0401 molecules and
subsequent cross-linking with streptavidin-PE [58]. To test whether
each tetramer were able to bind Ply specific tonsil CD4 T cells, anti-
Ply T cell lines were generated from blood CD4+ T cells of HLA
DRB1
*04 expressing individuals. Briefly, fresh PBMC were depleted
of CD8
+cells by magnetic cellsorting using anti-CD8 magnetic beads
(Miltenyi) according to the manufacturer’s guide and stimulated with
0.2 mg/ml Ply peptide in RPMI 1640 medium containing 10%
human serum. The plates were incubated at 37uCi n5 %C O 2,a n d
after7days,themediumwasreplaced and 25 U/mlIL-2 (Peprotech)
added. Cells were restimulated with peptide, IL-2 and irradiated
autologous PBMC every 12–14 days. Cell lines in 1% human serum
RPMI were stained with a tetramer presenting one of the four Ply
epitopes at 10 mg/ml for 1 hour at 37uC, 5% CO2. Subsequent
FACS analysis revealed tetramers presenting P1, P3 and P4 Ply
epitopes were bound by at least 6% of cells while P2 were bound by
,1% and used as a negative control.
Tetramer staining
CD4+CD25 enriched tonsillar MNC or PBMC from
HLADR0401 expressing subjects above 20 years old were
obtained by magnetic sorting using the CD4 CD25 enrichment
kit (Miltenyi Biotec) according to the manufacturers instruction
(typically .80% of cells were CD4
+ CD25
+). Enriched cells were
stained with either streptavidin-PE (Becton Dickenson) as a
negative control, P1, P3 and P4 tetramers at 10 mg/ml each or
30 mg/ml of P2 tetramer as an additional negative control as
previously. Cells were stained with anti-human CD4-PECy7
(Becton Dickenson), anti-human CD127-FITC (eBioscience)
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staining with anti-human FoxP3-APC (eBioscience) using FoxP3
staining buffer set (eBioscience) according to the manufacturer
instructions and subsequently analysed by FACS and FlowJo.
Statistical analysis
Distribution of the data was determined using the Kolmogorov-
Smirnov test. When data was found to be normally distributed,
differences between two groups were tested using paired or
unpaired students t- test accordingly. The Wilcoxon signed rank
test was used to test differences between undepleted MNC and
CD25 depleted groups following antigenic stimulation by SPSS
statistical analysis software (IBM). Two way ANOVA was used for
comparing results of untreated, flu, Ply and SPNT treated groups
and for the effect of Treg study and for comparing undepleted
MNC, CD25-depleted, IgG blocked and CTLA-4 or PDL-1
blocked groups in the CTLA-4 or PDL-1 blocking study by SPSS
statistical analysis software.
Accession numbers
Amino acid sequence for pneumolysin was obtained from
GenBank; Accession:ADF28490 (DBSOURCE - GU968411.1).
GI: 294652455.
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